FBRX

ANALYST NOTE: FORTe BIOSCIENCES, INC. (FBRX) DATE: 2026-06-13 CURRENT PRICE: $17.85

1. Structural Readiness

State: Context-Only Conservative Entry: — Current Price: $17.85 Extension: — ATR at Breakout: — ATR Current: 8.7% (Extreme) Pivot Strength: — Cap Bucket: Small Sector: Healthcare

Structural Analysis:

2. Thesis Layer

Thesis Classification: TACTICAL / Setup-Led Secular Thesis: None named at this date.

This is a tactical, setup-led name. There is no named macro or secular thesis driving the immediate conviction. The investment case must be judged strictly on the quality of the structural setup (the forming coil) and the underlying business fundamentals as reported by management. No external narrative or "story" should be invented to support the position; the thesis is the execution of the clinical pipeline and the structural price action.

3. Business Overview

Company Description: Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company developing proprietary anti-CD122 monoclonal antibody therapeutic candidates. The current lead product candidate is FB102 (formerly FB-401 in earlier iterations), designed for autoimmune and autoimmune-related indications.

Business Model & Industry: The company operates in the Healthcare sector, specifically within the biopharmaceutical industry. The model is asset-driven, relying on the advancement of clinical trials to generate value. The company does not currently have commercialized products generating revenue; its value is derived from the successful progression of its pipeline through regulatory milestones.

Supporting Evidence (As of 2026-06-13):

• Pipeline Progress (Celiac Disease): Management announced positive data in the Phase 1b celiac disease study in June 2025. Based on this success, they initiated a Phase 2 celiac study in July 2025, with a topline readout expected in 2026 (Evidence E9, E10, E15, E22).
• Pipeline Progress (Dermatology): The Phase 1b non-segmental vitiligo trial is ongoing with topline data expected in the first half of 2026. Additionally, a Phase 1b alopecia areata study was initiated with topline data expected in 2026 (Evidence E11, E16).
• Financial Position: As of December 31, 2025, the company held approximately $77.0 million in cash and cash equivalents (Evidence E21). This is an increase from the $54.8 million reported in Q1 2021 (Evidence E4), indicating capital preservation or recent financing.
• Market Opportunity: Management cites a global alopecia treatment market valued at $3-3.5 billion in 2024, projected to reach $6 billion by 2032-2034 (Evidence E13, E20). The celiac disease market includes an estimated 2.5 million people in the U.S., with a subset of non-responsive patients (Evidence E12).

4. Archetype and Conviction

Archetype: Growth Leader Rationale: The company fits the Growth Leader archetype due to its clinical-stage status with multiple high-potential indications (Celiac, Vitiligo, Alopecia) and a proprietary mechanism of action (anti-CD122). The "growth" here is defined by the binary nature of clinical trial readouts and the potential for regulatory approval, rather than current earnings.

Conviction Stack:

• Thesis Strength: Low (Tactical/Setup-led only; no macro thesis).
• Evidence Quality: Moderate to High. The evidence base is robust regarding the *status* of the pipeline (positive Phase 1b, initiated Phase 2, upcoming readouts). The financial data is clear ($77M cash).
• Setup Readiness: Partial. The coil is forming, but the breakout has not fired.
• Rerating Potential: High, contingent on the 2026 topline readouts for Celiac and Vitiligo.
• Volatility Context: The current ATR of 8.7% is Extreme. In the StoryStocks canon, extreme ATR (>8%) is associated with the highest historical severe-loser rate. This suggests that while the setup is forming, the risk of a false breakout or a sharp reversal is significant. The structural quality is currently overshadowed by the volatility risk.

5. Invalidations, Strengths, and Gaps

What Would Invalidate the Case:

• Fundamental: Failure of the Phase 2 Celiac readout (expected in 2026) or negative data from the Vitiligo/Alopecia trials.
• Financial: A significant dilution event or cash burn rate that threatens the $77M runway before the 2026 readouts.

What Would Strengthen the Case:

• Structural: A confirmed close above the resistance level (breakout), transitioning the coil to "Confirmed-Active."
• Fundamental: Positive topline data from the Phase 2 Celiac study or the Phase 1b Vitiligo study.
• Financial: Announcement of a strategic partnership or licensing deal.

Gaps in Evidence:

• Specific Catalyst Timing: While "expected in 2026" is stated, the exact month for the Celiac Phase 2 readout is not specified in the provided evidence (only "expected in 2026").
• Commercialization Plan: No evidence regarding post-approval commercialization strategy or manufacturing scale-up plans.
• Competitive Landscape: No specific evidence regarding competitive dynamics or alternative therapies in the Celiac or Alopecia markets beyond market size estimates.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: low Key evidence: Positive Phase 1b celiac data announced June 2025; Phase 2 study initiated July 2025 with 2026 readout; $77.0M cash position as of Dec 31, 2025. Sizing hint: Minimal position size due to extreme volatility and unconfirmed structural breakout. Expected path: Management expects topline data from Celiac Phase 2 and Vitiligo Phase 1b in 2026; price likely to remain volatile until catalysts resolve. Expected horizon: 6 to 12 months (aligned with 2026 topline readouts).